Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006367 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00006367: Completed Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
NCT00006367 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006367, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy followed by peripheral stem cell transplantation in treating patients who have myelofibrosis.
Interventions
- PROCEDURE peripheral blood stem cell transplantation
- BIOLOGICAL filgrastim
- DRUG cytarabine
- DRUG idarubicin
- DRUG busulfan
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-05 |
| Est. Completion | 2004-01 |
| Phase | Phase 2 |
What the finished NCT00006367 record still lists
NCT00006367 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which peripheral blood stem cell transplantation is the first listed.
NCT00006367 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006367 about?
NCT00006367 is a clinical study titled "Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase II tria...
What is the current status of trial NCT00006367?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-05. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00006367?
The interventions under investigation include: peripheral blood stem cell transplantation (PROCEDURE), filgrastim (BIOLOGICAL), cytarabine (DRUG), idarubicin (DRUG), busulfan (DRUG).
Who is sponsoring clinical trial NCT00006367?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia